Study of Immune Globulin Intravenous (Human) GC5107 in Pediatric Subjects With Primary Humoral Immunodeficiency

Exclusion Criteria

• •Subject who has a history of clinically significant reactions or hypersensitivity to IGIV or other injectable forms of IgG
• •Subject who has IgA deficiency and is known to have antibodies to IgA
• •Subject who has secondary immunodeficiency
• •Subject who has participated in another clinical study (other than an IGIV study) within 3 weeks prior to screening
• •Subject who has been diagnosed with dysgammaglobulinemia or isolated IgG subclass deficiency or isolated IgA deficiency, or who has clinically significant impairment of cellular or innate immunity at the discretion of the Investigator
• •Subject who has received blood products other than human albumin or human immune globulin within 6 months prior to enrollment